Metabolism-related fatty liver disease (MAFLD) is the most common form of chronic liver
disease in the world. Its pathogenesis is influenced by both environmental and genetic …

In light of a global rise in the number of patients with type 2 diabetes mellitus (T2DM) and
obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction …

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial condition with a complex
etiology. Its incidence is increasing globally in parallel with the obesity epidemic, and it is …

Metabolic-associated liver disease (MAFLD) affects up to 70% of overweight and more than
90% of morbidly obese people, and its pathogenesis is rather complex and multifactorial …

Obesity, and metabolic dysfunction-associated fatty liver disease (MAFLD) have reached
epidemic proportions globally. Obesity and MAFLD frequently coexist and act synergistically …

The epidemiological burden of liver steatosis associated with metabolic diseases is
continuously growing worldwide and in all age classes. This condition generates possible …

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is characterized by
intense deposition of fat globules in the hepatic parenchyma that could potentially progress …

Metabolic-associated fatty liver disease (MAFLD), formerly referred to as non-alcoholic fatty
liver disease (NAFLD), is a common liver disease characterized by an abnormal buildup of …

Excessive hepatic fat accumulation in the absence of high alcohol consumption, up to date
referred to as nonalcoholic fatty liver disease (NAFLD), has emerged in recent years as one …

Resmetirom (Rezdiffra™) is an oral thyroid hormone receptor-β (THR-β) agonist being
developed by Madrigal Pharmaceuticals, Inc., to target the key underlying causes of …